Draft:Gene Solutions
This article, Draft:Gene Solutions, has recently been created via the Articles for creation process. Please check to see if the reviewer has accidentally left this template after accepting the draft and take appropriate action as necessary.
Reviewer tools: Preload talk Inform author |
This article, Draft:Gene Solutions, has recently been created via the Articles for creation process. Please check to see if the reviewer has accidentally left this template after accepting the draft and take appropriate action as necessary.
Reviewer tools: Preload talk Inform author |
{{Connected contributor (paid)}} should only be used on talk pages.
Gene Solutions is a biotechnology company based in Ho Chi Minh City, Vietnam, that develops genetic testing services using next-generation sequencing.[1] Founded in 2017, it initially specialised in non-invasive prenatal testing (NIPT) and later expanded into cancer screening tests.[2][3]
The company was established by Nguyen Hoai Nghia (CEO), Nguyen Huu Nguyen, and Giang Hoa.[4] It has been described as the market leader in NIPT in Vietnam.[2][5]
Expansion
[edit | edit source]Gene Solutions started with prenatal testing in Vietnam and later grew into other Southeast Asian markets.[3] It opened a diagnostics lab and branch in Singapore to serve as a regional centre, and formed partnerships in countries including Thailand, Indonesia, the Philippines, and Malaysia.[2][6]
Funding
[edit | edit source]Mekong Capital invested $15 million in 2021 through its Mekong Enterprise Fund IV.[4] A follow-on Series B round in 2023 raised $21 million from the same fund to support oncology testing and regional growth.[5]
In November 2025, the company announced plans to raise up to $100 million through a pre-IPO round and a possible 2026 listing, potentially in Singapore or Hong Kong.[1]
Tests and research
[edit | edit source]Its main prenatal test is triSure, a non-invasive screening for chromosomal abnormalities.[2]
For cancer detection, Gene Solutions offers SPOT-MAS, a multi-cancer early detection test based on circulating tumor DNA analysis.[5] The underlying technology, involving multimodal analysis of cell-free DNA methylation and fragmentomics, underwent analytical validation in a case-control study and was published in the journal eLife in 2023.[7]
Clinical validation of SPOT-MAS has been reported in several independent studies, including an interim report from a prospective cohort of nearly 2,800 participants published in Cancer Investigation (2023),[8] and results from the large-scale K-DETEK prospective trial (over 9,000 asymptomatic participants) published in BMC Medicine.[9]
References
[edit | edit source]- ^ a b Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ a b c d Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ a b Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ a b Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ a b c Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).